Sho Hiroyasu
9PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Oct 24, 2025
Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report.Hiroyasu Kaneda, Lan Wang, Takako Oka
|Jun 12, 2025
Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano
|Oct 04, 2024
Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.Hiroaki Nagamine, Masakazu Yashiro, Megumi Mizutani
|Sep 15, 2024
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano
|Jul 03, 2021
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.Hiroyasu Kaneda, Kenji Sawa, Haruko Daga
|May 14, 2020
Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review.Koichi Ogawa, Hiroyasu Kaneda, Tamaki Kawamoto
Pageof 2
